A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma

Area of Science:

• Oncology
• Biomaterials Science
• Translational Medicine

Background:

• Osteosarcoma (OS) research has been hindered by a lack of effective preclinical models for over two decades.
• Identifying reliable predictive tumor markers is crucial for improving OS patient outcomes.
• Existing in vivo models often fail to accurately recapitulate the complex human bone tumor microenvironment.

Purpose of the Study:

• To investigate the impact of microenvironmental modifications in a novel humanized in vivo model on OS tumor marker expression.
• To assess the potential of specific OS markers, including HIF2α, as prognostic indicators and therapeutic targets.
• To validate findings from the preclinical model in human osteosarcoma patient cohorts.

Main Methods:

• Development of a humanized tissue-engineered bone organ (hTEBO) model using human bone chips and marrow implanted in NOD/scid mice.
• Modulation of the bone microenvironment using recombinant human bone morphogenetic protein 7 (rhBMP-7).
• Injection of human osteosarcoma cells (Luc-SAOS-2) into hTEBOs, followed by analysis of tumor marker expression (ezrin, periostin, VEGF, HIF1α, HIF2α) and validation in OS patient cohorts.

Main Results:

• The humanized bone organ model successfully recapitulated OS tumor marker expression.
• HIF2α was significantly upregulated in OS tumors within the rhBMP-7 modulated hTEBOs compared to controls.
• HIF2α expression in OS patients correlated with tumor site and clinical stage, and was suppressed post-chemotherapy.

Conclusions:

• The developed humanized bone organ model is clinically relevant for osteosarcoma research and marker validation.
• HIF2α demonstrates significant potential as a prognostic marker and/or therapeutic target for osteosarcoma.
• Further clinical studies are warranted to confirm the role of HIF2α in osteosarcoma prognosis and treatment.